{"DataElement":{"publicId":"2005695","version":"4","preferredName":"Common Toxicity Criteria Adverse Event Nystagmus Grade","preferredDefinition":"in CTC category Ocular/Visual, assessment of the severity of a nystagmus adverse event using a graded scale.","longName":"CTC_AE_NYSTAGMUS_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2194869","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Nystagmus","preferredDefinition":"information related to the CTC adverse event of nystagmus.","longName":"CTC_AE_NYSTAGMUS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2194867","version":"1","preferredName":"Nystagmus","preferredDefinition":"Involuntary movements of the eye that are divided into two types, jerk and pendular. Jerk nystagmus has a slow phase in one direction followed by a corrective fast phase in the opposite direction, and is usually caused by central or peripheral vestibular dysfunction. Pendular nystagmus features oscillations that are of equal velocity in both directions and this condition is often associated with visual loss early in life. (Adams et al., Principles of Neurology, 6th ed, p272)","longName":"Nystagmus","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Nystagmus","conceptCode":"C3282","definition":"Involuntary movements of the eyeballs. The presence or absence of nystagmus is often used in the diagnosis of a variety of neurological and visual disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC63A462-A676-05FA-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-30","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC63A462-A67C-05FA-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017895","version":"3","preferredName":"Common Toxicity Criteria Adverse Event Nystagmus Grade","preferredDefinition":"in CTC category Ocular/Visual, assessment of the severity of a nystagmus adverse event using a graded scale.","longName":"CTC_AE_NYSTAGMUS_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":"Asymptomatic","ValueMeaning":{"publicId":"2571651","version":"1","preferredName":"Asymptomatic","longName":"2571651v1.00","preferredDefinition":"Without clinical signs or indications that raise the possibility of a particular disorder or dysfunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asymptomatic","conceptCode":"C3833","definition":"Without clinical signs or indications that raise the possibility of a particular disorder or dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E4F0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-08-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4DB393A-2294-0474-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"0","valueDescription":"ABSENT","ValueMeaning":{"publicId":"2563534","version":"1","preferredName":"ABSENT","longName":"2563534","preferredDefinition":"ABSENT","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C53B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-23","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-10-23","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4DB393A-2296-0474-E034-0003BA12F5E7","beginDate":"2003-01-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Symptomatic and interfering with function but not interfering with ADL","ValueMeaning":{"publicId":"2566707","version":"1","preferredName":"Symptomatic and interfering with function but not interfering with ADL","longName":"2566707","preferredDefinition":"Symptomatic and interfering with function but not interfering with ADL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D1A0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-14","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4DAFC51-0F20-047E-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Symptomatic and interfering with ADL","ValueMeaning":{"publicId":"2566358","version":"1","preferredName":"Symptomatic and interfering with ADL","longName":"2566358","preferredDefinition":"Symptomatic and interfering with ADL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D043-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4DAFC51-0F22-047E-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"Disabling","ValueMeaning":{"publicId":"2566348","version":"1","preferredName":"Disabling","longName":"2566348","preferredDefinition":"Disabling","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D039-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-06","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-06","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4DAFC51-0F24-047E-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4DB393A-2290-0474-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-14","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"CTC Adverse Event Nystagmus G","type":"Preferred Question Text","description":"CTC Adverse Event Nystagmus Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Nystagmus Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C4DB369E-AF10-0478-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-14","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}